Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

51.68
+0.07000.14%
Post-market: 51.680.00000.00%17:53 EDT
Volume:288.37K
Turnover:14.64M
Market Cap:1.79B
PE:-13.19
High:51.81
Open:51.61
Low:49.73
Close:51.61
Loading ...

Disc Medicine price target raised to $73 from $70 at Scotiabank

TIPRANKS
·
22 Jan

Disc Medicine Shares Fall 6.8% After Co Commences $200 Mln Public Offering

THOMSON REUTERS
·
22 Jan

Disc Medicine Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
22 Jan

BUZZ-Disc Medicine slips on planned stock sale

Reuters
·
22 Jan

Disc Medicine Shares Fall 4% Premarket After Co Commences $200 Mln Public Offering

THOMSON REUTERS
·
22 Jan

Disc Medicine’s Bitopertin: Regulatory Progress and Accelerated Market Prospects Fuel Buy Rating

TIPRANKS
·
22 Jan

Disc Medicine Inc - Commences $200 Million Underwritten Offering

THOMSON REUTERS
·
22 Jan

Disc Medicine Inc - Proceeds to Fund Research and Clinical Development

THOMSON REUTERS
·
22 Jan

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
22 Jan

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
22 Jan

Disc Medicine Price Target Maintained With a $118.00/Share by HC Wainwright & Co.

Dow Jones
·
22 Jan

H.C. Wainwright Keeps Their Buy Rating on Disc Medicine (IRON)

TIPRANKS
·
22 Jan

Disc Medicine Reports 'Positive' Feedback From FDA Meeting

MT Newswires Live
·
22 Jan

Disc Medicine’s Promising Path: Buy Rating Backed by Regulatory Milestones and Market Potential

TIPRANKS
·
22 Jan

Disc Medicine Inc : Scotiabank Raises Target Price to $73 From $70

THOMSON REUTERS
·
21 Jan

Wedbush Raises Price Target on Disc Medicine to $90 From $83, Keeps Outperform Rating

MT Newswires Live
·
21 Jan

Disc Medicine announces feedback from Type C meeting with FDA

TIPRANKS
·
21 Jan

Disc Medicine Announces Successful Type C Meeting With FDA for Bitopertin in Erythropoietic Protoporphyria (Epp) and Shares Plans for Nda Submission

THOMSON REUTERS
·
21 Jan

Disc Medicine Inc - Planning to Submit Nda Under Accelerated Approval Pathway in H2 2025

THOMSON REUTERS
·
21 Jan

Disc Medicine : Plans to Initiate Apollo Trial by Mid-2025 and Will Include Sites in US, Canada, Europe, and Australia

THOMSON REUTERS
·
21 Jan